NMN & NR Supplementation ·
This study investigates the immunological fitness of NSCLC patients and its implications for treatment responses, particularly in older adults. As the population ages, understanding how immune responses change in older cancer patients becomes increasingly important. This research specifically examines how these changes may affect the efficacy of anti-PD1-based immunotherapies.
What this study examined
The study enrolled 78 patients diagnosed with non-small cell lung cancer (NSCLC), categorizing them into two age groups: younger patients under 65 years (26 participants) and older patients aged 65 years and above (52 participants). The researchers assessed the patients' immune profiles prior to therapy, employing flow cytometry and a Luminex assay to evaluate circulating immune cell subsets and soluble immune mediators. The primary outcomes included correlations between immune populations, treatment response, and survival outcomes, with a control group of 27 healthy donors for comparison.
Why this matters for longevity research
Understanding the immune system's response to therapies is crucial for improving treatment outcomes in older patients, who represent a growing demographic in cancer care. The findings highlight how age-related immune changes can influence the effectiveness of immunotherapies, which may have broader implications for healthspan and longevity. By identifying factors that contribute to immunological fitness, researchers can better tailor interventions aimed at enhancing longevity, particularly in aging populations.
Key findings
- Cancer patients exhibited higher levels of CD8, Ki67, effector, and regulatory T cells compared to healthy donors.
- Differences in immune profiles were consistent across age groups, although effector cells showed a slight increase in younger cancer patients.
- Significantly lower levels of CD3, CD4, PD1, and naïve T cells were observed in cancer patients compared to healthy donors.
- Young non-responders experienced longer survival than older non-responders, indicating age-related disparities in treatment response.
- PMN (Lox1 + )-MDSCs and Ki67 levels were identified as independent predictors of outcomes in non-responders.
- The study established a cut-off for distinguishing high-risk groups based on immune markers.
- Older non-responders showed higher levels of PMN (Lox1 + )-MDSCs compared to their responder counterparts.
The science behind it
The immune system plays a critical role in cancer treatment, particularly through mechanisms involving T cells and immune mediators. Nicotinamide riboside (NR) is known to influence NAD+ levels, which are essential for maintaining cellular health and supporting sirtuin activity. Sirtuins are proteins that regulate cellular processes, including aging and immune response. By enhancing NAD+ availability, NR may help improve immune function, potentially counteracting some age-related declines in immunological fitness. This interplay between NAD+ and immune health is particularly relevant in the context of cancer therapies, as effective immune responses are crucial for successful treatment outcomes.
How it fits into the longevity field
This research aligns with the broader literature on aging and cancer, emphasizing the importance of immune health in extending healthspan. Interventions such as nicotinamide riboside that enhance NAD+ levels could be pivotal in improving immune responses in older adults, thereby influencing longevity outcomes. Other studies have explored similar themes, investigating how lifestyle factors and pharmacological agents can modulate immune function and promote healthier aging.
Practical takeaways
Researchers and informed readers should consider the implications of immune aging on cancer treatment efficacy. Understanding how nicotinamide riboside and related interventions can enhance immunological fitness may lead to improved strategies for patient stratification and personalized therapy. Continued exploration of the relationship between NAD+ levels, immune function, and aging will be critical for advancing longevity research.
FAQ
How does age affect immune response in cancer patients?
Older cancer patients often exhibit changes in their immune profiles that can impact treatment effectiveness, as shown in this study.
What role does nicotinamide riboside play in aging?
Nicotinamide riboside is known to enhance NAD+ levels, which may improve immune function and support healthier aging.
Why is immunological fitness important for longevity?
Immunological fitness can influence treatment outcomes in cancer patients and is essential for extending healthspan and longevity.
Source: PubMed · J Transl Med · published 2026-02-14.